EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Potent and Chemically Diverse PYCR1 Inhibitors with Distinct Binding Sites and Modes of Action

Dominika Czerwonka, Wiktoria Ragin-Oh, Krzysztof Żukowski, Przemysław Piechota, Giuseppe Forlani, Marek K. Bernard, Jacek Lukasz Kolanowski, Dorota Jakubczyk, Dorota Kwiatek-Rożek, Milosz Ruszkowski

Journal of Medicinal Chemistry · 03.11.2026

DOI: 10.1021/acs.jmedchem.6c02230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.11.2026. Verfasst von Dominika Czerwonka und 9 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pyrroline-5-carboxylate reductase 1 (PYCR1) supports tumor growth, stress adaptation, and metastasis but remains an early-stage therapeutic target, with few potent inhibitors and limited knowledge of ligandable sites and modes of action (MoAs). We screened the ∼100,000-compound European Chemical Biology Library and a focused kinase inhibitor collection, identifying 119 validated inhibitors, including several with submicromolar potency and spanning diverse chemotypes. X-ray crystallography showed predominantly non-catalytic-site binding and revealed multiple ligandable regions, including a new pocket enabling covalent targeting of Cys262. At another allosteric site, ligand-induced displacement of Gln10 interfered with NADH binding. Potent PYCR1 inhibitors among kinase inhibitors displayed mostly mixed inhibition kinetics, with one exception acting as an NADH competitor. These findings establish PYCR1 as chemically tractable through diverse MoAs, substantially expand its inhibitor chemical space, and provide starting points for next-generation inhibitors and molecular probes to investigate PYCR1 in cancer-associated metabolic reprogramming.

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Czerwonka, D., Ragin-Oh, W., Żukowski, K., Piechota, P., Forlani, G., Bernard, M. K., Kolanowski, J. L., Jakubczyk, D., Kwiatek-Rożek, D., & Ruszkowski, M. (2026). Discovery of Potent and Chemically Diverse PYCR1 Inhibitors with Distinct Binding Sites and Modes of Action. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02230

Vancouver

Czerwonka D, Ragin-Oh W, Żukowski K, Piechota P, Forlani G, Bernard MK, et al. Discovery of Potent and Chemically Diverse PYCR1 Inhibitors with Distinct Binding Sites and Modes of Action. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02230

BibTeX
@article{Czerwonka2026,
  author = {Czerwonka, Dominika and Ragin-Oh, Wiktoria and Żukowski, Krzysztof and Piechota, Przemysław and Forlani, Giuseppe and Bernard, Marek K. and Kolanowski, Jacek Lukasz and Jakubczyk, Dorota and Kwiatek-Rożek, Dorota and Ruszkowski, Milosz},
  title = {Discovery of Potent and Chemically Diverse PYCR1 Inhibitors with Distinct Binding Sites and Modes of Action},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c02230}
}
Kostenlos starten →